Low-pro­file Be­yond­Spring files for $100M IPO to back can­cer work; Ery­tech ham­mered af­ter it pulls mar­ket­ing ap­pli­ca­tion

Be­yond­Spring Phar­ma­ceu­ti­cals, a low-pro­file biotech reg­is­tered in the Cay­man Is­lands with of­fices in New York and Chi­na, has filed for a $100 mil­lion IPO. The com­pa­ny’s main fo­cus is on plinab­u­lin, a drug it in-li­censed in 2013 and now plans to put it in­to a slate of late-stage stud­ies for neu­trope­nia as well as non-small cell lung can­cer. Its work on NSCLC re­volves around mid-stage da­ta col­lect­ed on a sub­set of pa­tients. And now it’s look­ing for in­vestor sup­port to pay for the R&D. Here’s the F-1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER